Page 25 - 《中国药房》2026年4期
P. 25

阳和汤加减对乳腺癌骨转移大鼠骨破坏的影响及机制研究
                                                                                                   Δ


          卢 舜 ,蔡 昂 ,樊婷婷 ,何威华 (1.武汉市中医医院肿瘤科,武汉 430050;2.武汉市中医医院骨伤科,
                          1
                                           1 #
                 1*
                                   2
          武汉 430050)
          中图分类号  R737.9;R965      文献标志码  A      文章编号  1001-0408(2026)04-0431-07
          DOI  10.6039/j.issn.1001-0408.2026.04.04

          摘  要  目的  基于受体相互作用蛋白激酶1(RIPK1)/RIPK3通路探讨阳和汤加减对乳腺癌骨转移大鼠骨破坏的改善作用及潜在
          机制。方法  以骨髓腔注射乳腺癌细胞悬液的方式构建乳腺癌骨转移大鼠模型,将造模成功的雌性大鼠随机分为模型组(灌胃等
          体积生理盐水),阳和汤加减低、中、高剂量组(分别灌胃相应药液1.30、2.60、5.20 g/kg,按生药量计),阳和汤加减高剂量+si-RIPK1
          组(灌胃相应药液5.20 g/kg,按生药量计;同时尾静脉注射RIPK1小干扰RNA),阳和汤加减高剂量+si-NC组(灌胃相应药液5.20
          g/kg,按生药量计;同时尾静脉注射阴性对照小干扰RNA),每组12只;另取12只健康大鼠作为对照组(灌胃等体积生理盐水);每
          天给药1次,持续14 d。称定各组大鼠给药前及末次给药后的体重;检测其机械性痛阈值、热痛阈值,观察其胫骨骨破坏情况、病
          理变化情况、破骨细胞形成情况;检测其胫骨组织中核因子κB受体活化因子(RANK)及其配体(RANKL)蛋白的阳性表达情况以
          及RIPK1、RIPK3、混合谱系激酶结构域样蛋白(MLKL)的磷酸化水平。结果  与对照组比较,模型组大鼠胫骨组织中肿瘤细胞明
          显增生并弥散浸润骨髓腔,并可见大片细胞肿瘤性坏死、骨破坏严重、骨皮质变薄、骨小梁受损;其体重(给药前及末次给药后)、机
          械性痛阈值、热痛阈值和 RIPK1、RIPK3、MLKL 的磷酸化水平均显著降低,肿瘤体积、胫骨骨破坏面积占比、破骨细胞数量和
          RANK、RANKL蛋白阳性表达均显著升高/增多/上调(P<0.05);与模型组比较,阳和汤加减低、中、高剂量组大鼠胫骨组织上述病
          理改变均有所缓解,各定量指标均呈剂量依赖性改善(P<0.05)。沉默RIPK1后,高剂量阳和汤加减的上述改善作用被显著减弱
         (P<0.05)。结论  阳和汤加减可减轻乳腺癌骨转移大鼠的骨破坏,上述作用可能与激活RIPK1/RIPK3通路有关。
          关键词  阳和汤加减;乳腺癌;骨转移;骨破坏;RIPK1/RIPK3通路

          Study  on  the  effect  and  mechanism  of  modified Yanghe  decoction  on  bone  destruction  in  rats  with  breast
          cancer bone metastasis
          LU Shun ,CAI Ang ,FAN Tingting ,HE Weihua(1. Dept. of Oncology, Wuhan Hospital of Traditional Chinese
                                         2
                 1
                           1
                                                     1
          Medicine,  Wuhan  430050,  China;2.  Dept.  of  Orthopedics  and  Traumatology,  Wuhan  Hospital  of  Traditional
          Chinese Medicine, Wuhan 430050, China)
          ABSTRACT   OBJECTIVE  To  explore  the  improvement  effect  and  potential  mechanism  of  modified  Yanghe  decoction  on  bone
          destruction  in  rats  with  breast  cancer  bone  metastasis  based  on  the  receptor-interacting  serine/threonine-protein  kinase  1 (RIPK1)/
          RIPK3  pathway.  METHODS  The  rat  model  of  breast  cancer  bone  metastasis  was  established  by  injecting  a  suspension  of  breast
          cancer cells into the bone marrow cavity. The rats with successful modeling were randomly divided into a model group (intragastric
          administration  of  equal  volume  of  normal  saline),  modified Yanghe  decoction  low-,  medium-,  and  high-dose  groups (intragastric
          administration  of  corresponding  decoction  at  1.30,  2.60  and  5.20  g/kg,  calculated  by  the  dosage  of  crude  drug),  high-dose
          modified Yanghe  decoction+si-RIPK1  group (intragastric  administration  of  corresponding  decoction  at  5.20  g/kg,  calculated  by  the
          dosage  of  crude  drug;  simultaneous  injection  of  small  interfering  RNA  for  RIPK1  via  the  tail  vein),  and  high-dose  modified
          Yanghe  decoction+si-NC  group (intragastric  administration  of  corresponding  decoction  at  5.20  g/kg,  calculated  by  the  dosage  of
          crude  drug;  simultaneous  injection  of  small  interfering  RNA  for  negative  control  via  the  tail  vein),  with  12  rats  in  each  group.
          Another 12 healthy rats were selected as the control group and were given the same volume of normal saline intragastrically, once a
          day,  for  14  consecutive  days.  Body  weight  was  measured  before  administration  and  at  the  end  of  the  last  administration.  The
          mechanical pain threshold and thermal pain threshold were measured, and the bone destruction, pathological changes and osteoclast
          formation  of  the  tibia  were  observed.  The  positive  expression  of  receptor  activator  of  nuclear  factor- κB (RANK)  and  receptor
                                                             activator  of  nuclear  factor- κB  ligand (RANKL)  in  the  tibial
             Δ  基金项目 湖 北 省 中 医 药 管 理 局 中 医 药 科 研 项 目(No.     tissue, as well as the phosphorylation levels of RIPK1, RIPK3
          ZY2023F054)                                        and  mixed  lineage  kinase  domain-like  protein (MLKL)  were
             *第一作者 主治医师,硕士。研究方向:恶性肿瘤的中西医结合
                                                             detected.  RESULTS  Compared  with  the  control  group,  the
          治疗。E-mail:guzemi@163.com
             # 通信作者 副主任医师,博士。研究方向:肿瘤疾病的中医药治                  tumor  cells  of  tibia  tissues  in  rats  of  the  model  group  showed
          疗。E-mail:thxxnp@163.com                            significant  proliferation  and  diffuse  infiltration  into  the  bone


          中国药房  2026年第37卷第4期                                                 China Pharmacy  2026 Vol. 37  No. 4    · 431 ·
   20   21   22   23   24   25   26   27   28   29   30